ARMP

Armata Pharmaceuticals, Inc. (ARMP) | Rumor.io

Armata Pharmaceuticals

ARMP

Attention (50-day avg)0%

Attention rank (50-day avg)#2,903

Bullish sentiment (50-day avg)88%

Price to earnings ratio-0.75

Market capitalization140.5M

Earnings per share-5.29

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-173.8M

Social

What share of all stock conversation is about ARMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 14

Armata Pharmaceuticals' stock rose 7.8% pre-market after receiving FDA Breakthrough Therapy designation for its AP-SA02 phage candidate targeting complicated Staphylococcus aureus bacteremia.
The FDA granted Breakthrough Therapy designation to AP-SA02 due to its 100% relapse-free rate at 28 days in Phase 2 data, compared to 75% on placebo.
Armata Pharmaceuticals' Breakthrough Therapy designation is a strong catalyst for its stock, with the company's phage therapy pipeline and clinical development attracting biotech momentum and attention.

Generated by AI

Sentiment

Of the messages about ARMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	86.67% -13.33	63.69% -18.31
Bearish	—	—	13.33% +13.33	36.31% +18.31

Bullish· Oct 24

$ARMP is expected to announce a phase 2 trial, which could lead to a significant increase in value to $50 in 6 months.
Armata Pharmaceuticals has secured a non-dilutive partner for its business, which will likely be announced on a big day and is expected to positively impact the stock.
Buying $ARMP calls for November 2025 with a strike price of $5 could yield a potential ROI of up to 57%.

Bearish· Oct 22

$ARMP's recent price jump may be due to manipulation, as evidenced by extreme order book activity and halted trades.
The company's phase 2 trials have a low approval rate, typically around 13%, which increases the likelihood of the stock price declining.
$ARMP's cash reserves are expected to be depleted in 9 months, necessitating a dilutive offering that could further depress the stock price.

Generated by AI

Topics

Of the messages about ARMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.88%	46.96%
Macro	—	0%	0%	23.48%
Technical Analysis	—	0%	25%	5.57%
Controversies	—	0%	3.13%	1.18%
Analysts	—	0%	0%	22.64%
Earnings	—	0%	0%	0.17%

Announcements· Oct 23

Armata Pharmaceuticals' Phase 1b/2a study of AP-SA02, a phage therapy for Staphylococcus aureus, has shown clinical efficacy against both MRSA and MSSA, with no evidence of relapse four weeks post-therapy.
The study's results support advancement into a pivotal Phase 3 trial, which Armata plans to initiate in 2026, subject to review and feedback from the FDA.
The Phase 1b/2a study was partially funded by a $26.2 million award from the U.S. Department of Defense, administered by the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC).

Technical Analysis· May 4

$ARMP needs to close above the 100 SMA on daily chart to head higher.
A wedge formation in $ARMP is setting up for a potential big run, with a possible monster move after lunch.
$ARMP's current support levels are 2.50 and 2.15, with a potential breakout over 3.00.

Generated by AI

Community

Of the messages about ARMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.67%	34.09%	11.87%
Newcomers	—	33.33%	65.91%	88.13%

Sep 14

Newcomers to the stock are focusing on its Breakthrough Therapy designation for AP-SA02, a bacteriophage-based drug for complicated Staphylococcus aureus infections.
The stock's recent price increase, up 21.38%, is attributed to the Breakthrough Therapy news and the company's well-capitalized status, with $24M cash and a new $28.7M non-dilutive award.
Armata Pharmaceuticals is being discussed as a biotech momentum setup, with a speculative bullish outlook due to its volatile price movements and the potential for positive clinical data and regulatory progress.

Generated by AI

News

Armata Pharmaceuticals Stock Slides after Pentagon Funding - Armata Pharmaceuticals (AMEX:ARMP)

Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.

6d agoBenzinga

Armata receives $3.7m DoW funding for phase 3 drug trial

7d agoInvesting.com

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

7d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data

7d agoInvesting.com

Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation

Armata Pharmaceuticals (AMEX:ARMP) shares rose 8% after the company said the US Food and Drug Administration granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin-sensitive S.

15d agoYahoo Finance

Also Discussed

Investors talking about ARMP also mention

#	Name	Attention
1	CareCloud Inc.CCLD	0%new
2	Eledon Pharmaceuticals, Inc.ELDN	0%0
3	Vince Holding Corp.VNCE	0%0
4	Protara Therapeutics, Inc.TARA	0%0
5	Western Copper and Gold CorporationWRN	0%0
6	Gyre Therapeutics Inc.GYRE	0%0
7	Peraso Inc.PRSO	0%0
8	GraniteShares Autocallable HOOD ETFAHD	0.02%-0.09
9	CareDx IncCDNA	0.01%+0.01
10	DarkHorse Technologies Inc.ANY	0%new

Armata Pharmaceuticals, Inc.

Healthcare
Biotechnology

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease. Its platform combines natural and synthetic bacteriophages with proprietary engineering, microbiological surveillance, and drug development capabilities to support product design, manufacturing, and clinical testing. Armata Pharmaceuticals operates as a specialist in infectious disease therapeutics, serving an important role in the broader biopharmaceutical market by advancing alternative approaches to conventional antibiotics.

Website

Location

5005 McConnell Avenue

Los Angeles, CA, 90066

United States

Social

What share of all stock conversation is about ARMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 14

Armata Pharmaceuticals' stock rose 7.8% pre-market after receiving FDA Breakthrough Therapy designation for its AP-SA02 phage candidate targeting complicated Staphylococcus aureus bacteremia.
The FDA granted Breakthrough Therapy designation to AP-SA02 due to its 100% relapse-free rate at 28 days in Phase 2 data, compared to 75% on placebo.
Armata Pharmaceuticals' Breakthrough Therapy designation is a strong catalyst for its stock, with the company's phage therapy pipeline and clinical development attracting biotech momentum and attention.

Generated by AI

Sentiment

Of the messages about ARMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	86.67% -13.33	63.69% -18.31
Bearish	—	—	13.33% +13.33	36.31% +18.31

Bullish· Oct 24

$ARMP is expected to announce a phase 2 trial, which could lead to a significant increase in value to $50 in 6 months.
Armata Pharmaceuticals has secured a non-dilutive partner for its business, which will likely be announced on a big day and is expected to positively impact the stock.
Buying $ARMP calls for November 2025 with a strike price of $5 could yield a potential ROI of up to 57%.

Bearish· Oct 22

$ARMP's recent price jump may be due to manipulation, as evidenced by extreme order book activity and halted trades.
The company's phase 2 trials have a low approval rate, typically around 13%, which increases the likelihood of the stock price declining.
$ARMP's cash reserves are expected to be depleted in 9 months, necessitating a dilutive offering that could further depress the stock price.

Generated by AI

Topics

Of the messages about ARMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.88%	46.96%
Macro	—	0%	0%	23.48%
Technical Analysis	—	0%	25%	5.57%
Controversies	—	0%	3.13%	1.18%
Analysts	—	0%	0%	22.64%
Earnings	—	0%	0%	0.17%

Announcements· Oct 23

Armata Pharmaceuticals' Phase 1b/2a study of AP-SA02, a phage therapy for Staphylococcus aureus, has shown clinical efficacy against both MRSA and MSSA, with no evidence of relapse four weeks post-therapy.
The study's results support advancement into a pivotal Phase 3 trial, which Armata plans to initiate in 2026, subject to review and feedback from the FDA.
The Phase 1b/2a study was partially funded by a $26.2 million award from the U.S. Department of Defense, administered by the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC).

Technical Analysis· May 4

$ARMP needs to close above the 100 SMA on daily chart to head higher.
A wedge formation in $ARMP is setting up for a potential big run, with a possible monster move after lunch.
$ARMP's current support levels are 2.50 and 2.15, with a potential breakout over 3.00.

Generated by AI

Community

Of the messages about ARMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.67%	34.09%	11.87%
Newcomers	—	33.33%	65.91%	88.13%

Sep 14

Newcomers to the stock are focusing on its Breakthrough Therapy designation for AP-SA02, a bacteriophage-based drug for complicated Staphylococcus aureus infections.
The stock's recent price increase, up 21.38%, is attributed to the Breakthrough Therapy news and the company's well-capitalized status, with $24M cash and a new $28.7M non-dilutive award.
Armata Pharmaceuticals is being discussed as a biotech momentum setup, with a speculative bullish outlook due to its volatile price movements and the potential for positive clinical data and regulatory progress.

Generated by AI

Armata Pharmaceuticals

Social

Sep 14

Bullish· Oct 24

Bearish· Oct 22

Announcements· Oct 23

Technical Analysis· May 4

Sep 14

Armata Pharmaceuticals Stock Slides after Pentagon Funding - Armata Pharmaceuticals (AMEX:ARMP)

Armata receives $3.7m DoW funding for phase 3 drug trial

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data

Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation

Also Discussed

Armata Pharmaceuticals, Inc.

Company Information

Location

Armata Pharmaceuticals Stock Slides after Pentagon Funding - Armata Pharmaceuticals (AMEX:ARMP)

Armata receives $3.7m DoW funding for phase 3 drug trial

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data

Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation

Also Discussed

Social

Sep 14

Bullish· Oct 24

Bearish· Oct 22

Announcements· Oct 23

Technical Analysis· May 4

Sep 14